ATP7B Antibody - #AF0410

Fig. 3 Blocked platinum efflux and enhanced ER stress by HSA@Pt combined with TM in vitro. (Aand B) Proteins expression levels of apoptosis-related proteins and PD-L1 in A549 cells after various treatments as mentioned above for 24 h by Western blot. Tubulin and β-actin were used as the internal reference protein. 1: PBS; 2: CisPt; 3: Pt(IV); 4: HSA@Pt; 5:TM; 6: CisPt+TM; 7: Pt(IV)+TM; 8: HSA@Pt+TM; (C) Representative CLSM images to show the ATP7B expression in A549 cells with various treatments. Scalar bar: 50 μm. (D) PD-L1 expression in A549 cells after various treatments by flow cytometry and (E) the corresponding quantification of PD-L1 expression. (F) Schematic illustration of possible mechanism of HSA@Pt combined with TM for antitumor activity. (G) Flow cytometry analysis and (H) quantitative study of DC maturation co-cultured with A549 cells with various treatments. n = 3. Data are presented as mean ± SD. Statistical significances between every two groups were calculated via one-way ANOVA with Tukey’s multiple comparisons test. *p 

FIGURE 3 CircSpna2 reduces cuproptosis in traumatic brain injury (TBI) mice. (A) Copper ion concentrations in circSpna2-overexpressing (oe-circSpna2) or knockdown (sh-circSpna2) mice post-TBI (n = 5 per group). (B) Mitochondrial complex I levels in circSpna2-overexpressing or knockdown mice 3 days post-TBI (n = 5 per group). (C) Mitochondrial complex III levels in circSpna2-overexpressing or knockdown mice 3 days post-TBI (n = 5 per group). (D and E) Expression of Atp7b, Lip-dlat, Lip-dlst, Lias, Sdhb and Fdx1 in circSpna2-overexpressing (D) or knockdown (E) mice 3 days post-TBI determined by western blotting (n = 5 per group). Detailed p values for each comparison are provided. Data are presented as the mean ± SEM. One-way analysis of variance (ANOVA) was used, followed by Tukey's multiple comparisons test. *p < .05, **p < .01, ***p < .001, ****p < .0001, ns, not significant.

Figure. 9 Functional experiments against NFE4 in Caki-1 and OS-RC-2 cells. A NFE4 was highly expressed in tumor tissues. B The expression of NFE4 in renal cancer cells was measured using real-time quantitative reverse transcription-PCR. C Survival analysis of the high NFE4 group and low NFE4 group. D, E The mRNA expression of NFE4 in Caki-1 and OS-RC-2 cells was measured using real-time quantitative reverse transcription-PCR. F, G Cell Counting Kit-8 assays were used to detect the effect of NFE4 knockdown on cell proliferation in Caki-1 and OS-RC-2 cells. H qRT-PCR shows the expression and regulation of NFE4 in Caki-1 and OS-RC-2 cells treated with drugs that induce cuproptosis for 24 h (n = 3). CuCl2 (2mM), Elesclomol (20 nM), both CuCl2 (2mM) and Elesclomol (20 nM). I Western blotting was used to determine the protein levels of ATP7B and SLC31A1 in Caki-1 and OS-RC-2 cells. One-way ANOVA, NC was used as a control group. Data are shown as the mean ± standard deviation from three independent experiments and were compared to the respective si-NC group. ****P < 0.0001; ***P < 0.001; **P < 0.01 and *P < 0.05.